Surgical Experience with Nonfunctioning Neuroendocrine Tumors of the Pancreas

Matthews, Brent D.; Heniford, B. Todd; Greene, Fredrick L.; Reardon, Patrick R.; Brunicardi, F. Charles
December 2000
American Surgeon;Dec2000, Vol. 66 Issue 12, p1116
Academic Journal
Nonfunctioning neuroendocrine tumors of the pancreas are rare slow-growing tumors with a more indolent natural history compared with pancreatic adenocarcinoma. This retrospective report reviews the surgical experience with nonfunctioning neuroendocrine tumors in an academic referral center. Statistical analysis was performed using Student's t test and Kaplan-Meier method compared with log-rank tests. Thirty-eight patients (24 males and 14 females) underwent surgery for a neuroendocrine tumor of the pancreas from 1984 through 1999. Twenty-eight patients with a mean age of 59.9 years had nonfunctioning islet cell tumors and 10 patients with a mean age of 59.1 years had functioning islet cell tumors (four gastrinomas, three glucagonomas, two insulinomas, and one vipoma). The nonfunctioning islet cell tumors were located in the head, neck, or uncinate process in 14 patients (50%), the body in seven (25%), and the tail in seven (25%). Operative procedures for the nonfunctioning islet cell tumors included nine pancreaticoduodenectomies, 12 distal pancreatectomies, three palliative bypasses, and four exploratory laparotomies without a resection or bypass. Mean survival for the four patients explored and not resected or bypassed was 7 months. Median survival for node-negative patients was 124 months, for node-positive patients 75 months, and for patients with metastasis to the liver 9 months. Estimated 2-year actuarial survival for the node-negative patients was 77.8 per cent, for node-positive patients 71.4 per cent, and for patients with metastasis to the liver 36.4 per cent. Six patients (60%) with node-negative disease, three (43%) with node-positive disease, and one (9%) with metastasis to the liver are alive at a mean follow-up of 41.8 months (range 1-167). Significant differences in median survival and 2-year survival were demonstrated between the node-positive/node-negative patients and those with metastasis to the liver (P = 0.003). Patients with localiz...


Related Articles

  • Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors. Fjällskog, Marie-Louise H.; Janson, Eva T.; Falkmer, Ursula G.; Vatn, Morten H.; Öberg, Kjell E.; Eriksson, Barbro K. // Neuroendocrinology;Jul2008, Vol. 88 Issue 1, p53 

    Treatment with combined streptozotocin and liposomal doxorubicin is safe and efficient in patients with endocrine pancreatic tumors (EPTs). No cardiac toxicity was reported. Background: The combination of streptozotocin and doxorubicin has been shown to be superior to streptozotocin and...

  • The Role of Combined Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors. Partelli, Stefano; Rinzivillo, Maria; Maurizi, angela; Panzuto, Francesco; Salgarello, Matteo; Polenta, Vanessa; Delle Fave, Gianfranco; Falconi, Massimo // Neuroendocrinology;Feb2015, Vol. 100 Issue 4, p293 

    Purpose: The aim of this study was to evaluate the effect of combined 68Ga and 18F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven...

  • In brief ...  // Gastrointestinal Nursing;Jul/Aug2017, Vol. 15 Issue 6, p10 

    This section offers news briefs on gastrointestinal nursing in Great Britain as of July 2017 including a resource to help carers provide support to those who need palliative care, the risk for obese women to have a baby with serious birth defects, and a blood test that detects a combination of...

  • Future Perspectives on Endoscopic Ultrasonography-Guided Therapy for Pancreatic Neoplasm. Woo Hyun Paik; Sang Hyub Lee; Sunguk Jang // Clinical Endoscopy;2018, Vol. 51 Issue 3, p229 

    Endoscopic ultrasonography (EUS)-guided therapy with ethanol injection or catheter-based radiofrequency ablation for pancreatic neoplasm has been conducted as a potential alternate treatment modality for patients who are not eligible for surgery. On the basis of the limited number of studies...

  • Laparoscopic Resection of a Giant Solid Pseudopapillary Neoplasm of Uncinate Process of the Pancreas in a Child. Tsai, Feng-Ji; Lee, Jui-Ying; Chang, Yu-Tang // Journal of Laparoendoscopic & Advanced Surgical Techniques;Dec2011, Vol. 21 Issue 10, p979 

    Solid pseudopapillary neoplasm of the pancreas in children is rare, and the most common localization of the tumor is the tail. The authors encountered such a case in a 10-year-old girl with a giant solid pseudopapillary neoplasm at the uncinate process of the pancreas. Imaging examination showed...

  • ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Falconi, M.; Eriksson, B.; Kaltsas, G.; Bartsch, D.K.; Capdevila, J.; Caplin, M.; Kos-Kudla, B.; Kwekkeboom, D.; Rindi, G.; Klöppel, G.; Reed, N.; Kianmanesh, R.; Jensen, R.T. // Neuroendocrinology;Apr2016, Vol. 103 Issue 2, p153 

    The article discusses updates to the consensus guidelines of medical personnel society European Neuroendocrine Tumor Society (ENETS) for the diagnosis and treatment of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Topics of the...

  • ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Garcia-Carbonero, R.; Sorbye, H.; Baudin, E.; Raymond, E.; Wiedenmann, B.; Niederle, B.; Sedlackova, E.; Toumpanakis, C.; anlauf, M.; Cwikla, J.B.; Caplin, M.; O''Toole, D.; Perren, a. // Neuroendocrinology;Apr2016, Vol. 103 Issue 2, p186 

    The article discusses updates to the consensus guidelines of medical personnel society European Neuroendocrine Tumor Society (ENETS) for the diagnosis and treatment of patients with gastroenteropancreatic and neuroendocrine carcinoma. Topics of the consensus guideline include the characteristics...

  • Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). Ramage, John K.; Punia, Pankaj; Faluyi, Olusola; Frilling, Andrea; Meyer, Tim; Saharan, Ruby; Valle, Juan W. // Neuroendocrinology;Jun2019, Vol. 108 Issue 4, p317 

    Background/Aims: To assess health-related quality of life (HRQoL), treatment patterns, and clinical outcomes of adult (≥18 years) patients with advanced (unresectable or metastatic) pancreatic neuroendocrine neoplasms (PanNENs) treated with everolimus in routine clinical practice. Methods:...

  • Gastrinomas: Advances in Diagnosis and Management. Jensen, Robert T. // Neuroendocrinology;Oct2004 Supplement 1, Vol. 80, p23 

    Gastrinomas causing Zollinger-Ellison syndrome (ZES) are the most common functional, malignant pancreatic endocrine tumors. In this paper, the diagnosis and treatment of these tumors are reviewed, incorporating recent advances in each area. Furthermore, recent advances in their pathology,...

  • Treatment with the Radiolabelled Somatostatin Analog Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. Sansovini, Maddalena; Severi, Stefano; ambrosetti, alice; Monti, Manuela; Nanni, Oriana; Sarnelli, anna; Bodei, Lisa; Garaboldi, Lucia; Bartolomei, Mirco; Paganelli, Giovanni // Neuroendocrinology;Jun2013, Vol. 97 Issue 4, p347 

    Background: We evaluated the activity and safety profile of 177Lu-DOTATATE peptide receptor radionuclide therapy (Lu-PRRT) in patients with advanced G1-G2 pancreatic neuroendocrine tumors. Patients and Methods: Fifty-two consecutive patients were treated at two different therapeutic dosages of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics